This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gerondelis, P.
Right arrow Articles by Demeter, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gerondelis, P.
Right arrow Articles by Demeter, L. M.

 Previous Article  |  Next Article 

Journal of Virology, July 1999, p. 5803-5813, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

The P236L Delavirdine-Resistant Human Immunodeficiency Virus Type 1 Mutant Is Replication Defective and Demonstrates Alterations in both RNA 5'-End- and DNA 3'-End-Directed RNase H Activities

Peter Gerondelis,1,2 Richard H. Archer,1 Chockalingam Palaniappan,3,dagger Richard C. Reichman,1,2 Philip J. Fay,1,3,4 Robert A. Bambara,2,3,4 and Lisa M. Demeter1,2,4,*

Departments of Medicine,1 Microbiology and Immunology,2 and Biochemistry and Biophysics3 and Cancer Center,4 University of Rochester School of Medicine and Dentistry, Rochester, New York 14642

Received 28 December 1998/Accepted 19 April 1999

The nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) delavirdine (DLV) selects in vitro for the human immunodeficiency virus type 1 (HIV-1) RT mutation P236L, which confers high-level resistance to DLV but not other NNRTIs. Unexpectedly, P236L has developed infrequently in HIV-1 isolates obtained from patients receiving DLV; K103N is the predominant resistance mutation observed in that setting. We characterized the replication fitness of viruses derived from pNL4-3 containing P236L or K103N in both H9 and primary human peripheral blood mononuclear cell cultures infected in parallel with the two mutants. In the absence of DLV, p24 production by wild-type virus occurred more rapidly and to higher levels than with either mutant; P236L consistently demonstrated a two- to threefold decrease in p24 relative to K103N. At low levels of DLV, growth of wild-type virus was severely inhibited, and K103N replicated two- to threefold more efficiently than P236L. At high concentrations of DLV, P236L replication and K103N replication were both inhibited. Recombinant RTs containing K103N or P236L were analyzed for DNA polymerization on heteropolymeric RNA templates and RNase H degradation of RNA-DNA hybrids. Neither mutant demonstrated defects in polymerization. K103N demonstrated normal RNA 5'-end-directed RNase H cleavage and slowed DNA 3'-end-directed RNase H cleavage compared to wild-type RT. P236L demonstrated slowing of both DNA 3'-end- and RNA 5'-end-directed RNase H cleavage, consistent with its reduced replication efficiency relative to K103N. These data suggest that NNRTI resistance mutations can lead to reductions in the efficiency of RNase H cleavage, which may contribute to a reduction in the replication fitness of HIV-1.

* Corresponding author. Mailing address: University of Rochester Medical Center, Infectious Diseases Unit, Box 689, 601 Elmwood Ave., Rochester, NY 14642. Phone: (716) 275-4764. Fax: (716) 442-9328. E-mail: Lisa_Demeter{at}urmc.rochester.edu.

dagger Present address: Amersham Pharmacia Biotech, Inc., Cleveland, OH 44128.

Journal of Virology, July 1999, p. 5803-5813, Vol. 73, No. 7
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Held, D. M., Kissel, J. D., Saran, D., Michalowski, D., Burke, D. H. (2006). Differential Susceptibility of HIV-1 Reverse Transcriptase to Inhibition by RNA Aptamers in Enzymatic Reactions Monitoring Specific Steps during Genome Replication. J. Biol. Chem. 281: 25712-25722 [Abstract] [Full Text]  
  • Dykes, C., Wang, J., Jin, X., Planelles, V., An, D. S., Tallo, A., Huang, Y., Wu, H., Demeter, L. M. (2006). Evaluation of a Multiple-Cycle, Recombinant Virus, Growth Competition Assay That Uses Flow Cytometry To Measure Replication Efficiency of Human Immunodeficiency Virus Type 1 in Cell Culture. J. Clin. Microbiol. 44: 1930-1943 [Abstract] [Full Text]  
  • Wu, H., Huang, Y., Dykes, C., Liu, D., Ma, J., Perelson, A. S., Demeter, L. M. (2006). Modeling and Estimation of Replication Fitness of Human Immunodeficiency Virus Type 1 In Vitro Experiments by Using a Growth Competition Assay. J. Virol. 80: 2380-2389 [Abstract] [Full Text]  
  • Hazen, R. J., Harvey, R. J., St. Clair, M. H., Ferris, R. G., Freeman, G. A., Tidwell, J. H., Schaller, L. T., Cowan, J. R., Short, S. A., Romines, K. R., Chan, J. H., Boone, L. R. (2005). Anti-Human Immunodeficiency Virus Type 1 Activity of the Nonnucleoside Reverse Transcriptase Inhibitor GW678248 in Combination with Other Antiretrovirals against Clinical Isolate Viruses and In Vitro Selection for Resistance. Antimicrob. Agents Chemother. 49: 4465-4473 [Abstract] [Full Text]  
  • Huang, W., Gamarnik, A., Limoli, K., Petropoulos, C. J., Whitcomb, J. M. (2003). Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus Replication. J. Virol. 77: 1512-1523 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
  • Nowicki, M. J., Benning, L., Bremer, J. W., Meyer, W. A. III, Hanson, C., Brambilla, D., Silver, S., Kovacs, A., Women's Interagency HIV-1 Study Collaborative Stud, (2001). Longitudinal Variability of Human Immunodeficiency Virus Type 1 RNA Viral Load Measurements by Nucleic Acid Sequence-Based Amplification and NucliSens Assays in a Large Multicenter Study. J. Clin. Microbiol. 39: 3760-3763 [Abstract] [Full Text]  
  • KRYNETSKAIA, N. F., FENG, J. Y., KRYNETSKI, E. Y., GARCIA, J. V., PANETTA, J. C., ANDERSON, K. S., EVANS, W. E. (2001). Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB J. 15: 1902-1908 [Abstract] [Full Text]  
  • Buckheit, R. W. Jr., Watson, K., Fliakas-Boltz, V., Russell, J., Loftus, T. L., Osterling, M. C., Turpin, J. A., Pallansch, L. A., White, E. L., Lee, J.-W., Lee, S.-H., Oh, J.-W., Kwon, H.-S., Chung, S.-G., Cho, E.-H. (2001). SJ-3366, a Unique and Highly Potent Nonnucleoside Reverse Transcriptase Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) That Also Inhibits HIV-2. Antimicrob. Agents Chemother. 45: 393-400 [Abstract] [Full Text]  
  • Joly, V., Moroni, M., Concia, E., Lazzarin, A., Hirschel, B., Jost, J., Chiodo, F., Bentwich, Z., Love, W. C., Hawkins, D. A., Wilkins, E. G. L., Gatell, A. J., Vetter, N., Greenwald, C., Freimuth, W. W., de Cian, W., The M/3331/0013B Study Group, (2000). Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial. Antimicrob. Agents Chemother. 44: 3155-3157 [Abstract] [Full Text]  
  • Archer, R. H., Dykes, C., Gerondelis, P., Lloyd, A., Fay, P., Reichman, R. C., Bambara, R. A., Demeter, L. M. (2000). Mutants of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase Resistant to Nonnucleoside Reverse Transcriptase Inhibitors Demonstrate Altered Rates of RNase H Cleavage That Correlate with HIV-1 Replication Fitness in Cell Culture. J. Virol. 74: 8390-8401 [Abstract] [Full Text]  
  • Demeter, L. M., Shafer, R. W., Meehan, P. M., Holden-Wiltse, J., Fischl, M. A., Freimuth, W. W., Para, M. F., Reichman, R. C. (2000). Delavirdine Susceptibilities and Associated Reverse Transcriptase Mutations in Human Immunodeficiency Virus Type 1 Isolates from Patients in a Phase I/II Trial of Delavirdine Monotherapy (ACTG 260). Antimicrob. Agents Chemother. 44: 794-797 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»